AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04404140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered at a dose of 75 mg/m\^2, as per the dosing schedule described above.
Study NCT03887962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Environment Biofeedback
Description: Treadmill walking. Modified available technology for gait capture. Tailored software for virtual environment rendering and immersive qualities
Study NCT03887962 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill walking with no Virtual Environment Biofeedback
Description: Treadmill walking. Flat screen / no virtual environment to act as attentional control.
Study NCT03992911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simmtecan, 5-FU and l-LV
Description: Simmtecan was administered intravenously at 80 mg per square meter on day1 with LV 400 mg per square meter administered as a 2-hour infusion, and 5-FU 2400 mg per square meter as a 46-hour infusion on day1 every 2 weeks in one course.
Study NCT03992911 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab was administered intravenously at 240 mg on day 1 every 2 weeks in one course.
Study NCT03992911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide, Cisplatin
Description: Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 with Cisplatin at 80 mg per square meter on day 1 every 3 weeks in one course.
Study NCT03992911 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide, Carboplatin
Description: Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 and Carboplatin with AUC 5mg/mL/min on day 1 every 3 weeks in one course.
Study NCT02803840 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Low-dose radiotherapy
Description: 2 x 2 Gy on symptomatic sites only
Study NCT03461887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-based exercise training program that requires only minimal equipment, and is individually adaptable to the participant's exercise level (6 times per week; 15-20 min; 38 exercise cards and one interactive training agenda booklet). After randomization, a health care professional (HOMEX coach) will visit the intervention group participants at their home to set up the training location, to instruct the exercises and to establish individualized goals. Follow-up visits are planned after 3 and 8-9 weeks. Regular telephone calls will be conducted by the same HOMEX coach to motivate the patients, to discuss training progress and concrete benefits and barriers, and to adapt goals and the training program. Additional intervention elements are that a relative or friend is involved as a sparring partner to support the participant. The general practitioner is informed about the participation of his/her patient in the intervention.
Study NCT01314495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Abatacept will be administrated as a 30 minute intravenous infusion.
Study NCT01314495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inactive infusion
Description: Placebo will be administered as a 30 minute intravenous infusion.
Study NCT01141179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 27847
Description: 2 mL (0.1 mg) dose of oral solution
Study NCT05455944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Two capsules of pregabalin is administered orally to patients
Study NCT05455944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two identical placebo capsules is administered orally to patients
Study NCT04061382 — intervention group
Intervention type: PROCEDURE
Intervention: Oral fluid swab
Description: Saliva sampling will be collected during the follow-up visits. This swab will be collected either by the participant or the participants parent/guardian on the day of the visit. The saliva sampling will primarily be analysed for SARS-CoV-2 antibodies.
Study NCT01235429 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partners in Care
Description: Participants will be offered 12 group diabetes self-management educational lessons delivered by trained community health workers.
Study NCT06229782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Orbital Doppler ultrasonography
Description: During measurement, Doppler settings were adjusted to detect low flow and the smallest available Doppler gate was used for all ODUS examinations. The imaging probe position for ODUS was used transversely and axially, and mean values were recorded. ODUS 10-18 MHz linear probe was used.
Study NCT06229782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Transcranial Doppler ultrasonography
Description: During the measurement, Doppler settings were adjusted to detect low flow, and the minor available Doppler gate was used for all TDUS examinations. For TDUS, a temporal window was used approximately 1 cm above the midpoint of the line joining the lateral palpebral fissure and the external auditory meatus.~Transcranial Doppler ultrasonography ( TDUS) 3-5 MHz convex array probe was used.
Study NCT06229782 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Computed Tomography Angiography
Description: Cranial Computed Tomography Angiography
Study NCT02225509 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FNA biopsy for thyroid nodule(s)
Description: The study is intended for patients for whom a FNA biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. FNA biopsy should preferably be carried out under ultrasound guidance. The FNA samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis. The patients will also be invited to take part in the mutation study in a separate consent form.~The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit.
Study NCT03512990 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bupivacaine - Superior Trunk Block
Description: It will be performed the superior trunk approach with local anesthestic in patients and methylene blue in cadavers.
Study NCT02684487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D3
Description: Patients will be given 400,000 IU of vitamin D3 within 24 hours of severe sepsis onset followed by weekly doses of 25,000 IU until 90 days or death, whichever comes first.
Study NCT02684487 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
Study NCT02218983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)
Study NCT02218983 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Study NCT02811484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Exenatide-LAR plus Dapagliflozin placebo
Description: Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.
Study NCT02811484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide-LAR plus Dapagliflozin
Description: Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.
Study NCT02811484 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Insulin Titration
Description: Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c>8%
Study NCT02811484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin Titration
Description: Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c>8%
Study NCT02811484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Titration
Description: Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c>8%
Study NCT02811484 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Therapy
Description: Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
Study NCT02811484 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Behavioral Therapy
Description: Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
Study NCT02811484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
Study NCT02183025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Study NCT02183025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Study NCT02183025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefenamic acid 500 mg
Study NCT02183025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching 7.5 mg meloxicam
Study NCT02183025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching 7.5 mg meloxicam
Study NCT00121173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
Description: recombinant DNA vaccine
Study NCT02183025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo matching 15 mg meloxicam
Study NCT02183025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching 15 mg meloxicam
Study NCT02183025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching 500 mg mefenamic acid
Study NCT03110731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Physical training (2x / week) was performed for 12 weeks
Study NCT00721266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5083945
Description: Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
Study NCT00781508 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sildenafil
Description: Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
Study NCT00781508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
Study NCT00781508 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Changes in left ventricular filling pressure 1 hour after oral administration of placebo
Study NCT00781508 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Changes in left ventricular filling pressure 1 hour after oral administration of placebo
Study NCT03988413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 25mg
Description: SYHA1402 25mg or Placebo 25mg
Study NCT03988413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg
Description: SYHA1402 50mg or Placebo 50mg
Study NCT03988413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg
Description: SYHA1402 100mg or Placebo 100mg
Study NCT03988413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg
Description: SYHA1402 200mg or Placebo 200mg
Study NCT03988413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg
Description: SYHA1402 400mg or Placebo 400mg
Study NCT03988413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 800mg
Description: SYHA1402 800mg or Placebo 800mg
Study NCT03325699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMART4MD Health Application
Description: SMART4MD is a general health application which has been adapted specifically for people with mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal carers. The application is optimized for tablet devices running on Android operating system (OS). Participants will be provided with a tablet with the SMART4MD health application.~The core functionalities of the application are based on reminders (medication, appointments with healthcare providers), brain supporting activities (clock, calendar, brain games, photos) and optional status and health information sharing with family and informal carers (including daily feeling status, specific health problems, and quality of life). An important feature of SMART4MD is its personalization facility: main users (PWD and informal carers) will be able to switch off/on various features and information sharing possibilities.
Study NCT03448055 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Immunocal
Description: cysteine-rich whey protein isolate
Study NCT02487628 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HQ® Matrix Soft Tissue Mesh
Study NCT02487628 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ULTRAPRO® Partially Absorbable Lightweight Mesh
Study NCT03882008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: All the subjects will receive Abatacept subcutaneous injection once a week for 24 weeks
Study NCT02545140 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT03271996 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fistulectomy
Description: Evaluation of the cavity using a 0.5-1 mm metal probe which will be inserted into the skin orifice. Excision of the skin around the orifice and debridement/excision of the cavity by monopolar scalpel or Trephines
Study NCT03046173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concentrated growth factors
Description: These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
Study NCT03046173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hydroxyapatite and autogenous bone
Description: These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
Study NCT03110744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: application on 21 consecutive days of a 28 days cycle
Study NCT00117286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
Study NCT03411915 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XmAb18087
Description: monoclonal bispecific antibody
Study NCT03531034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Exercise Training
Description: The program consisted of 30 sessions of combined aerobic and resistance exercises training during 10 consecutive weeks. Each session lasted 45 minutes and consisted of 5 minutes warm-up, 20 minutes of resistance exercise and 20 minutes of aerobic exercise. The resistance training was performed in two sets of 15 repetitions in seven exercises of weight training (Based on 1 repetition maximum test - 1RM) for large muscle groups. The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between ventilatory threshold 1 and 2 intensities. After 5 weeks of training, 1RM test was performed again to readjust the resistance load and aerobic intensity was readjusted by heart rate predicted in the incremental test.
Study NCT03531034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Exercise Training
Description: The program consisted of 30 sessions of combined aerobic and resistance exercises training during 10 consecutive weeks. Each session lasted 45 minutes and consisted of 5 minutes warm-up, 20 minutes of resistance exercise and 20 minutes of aerobic exercise. The resistance training was performed in two sets of 15 repetitions in seven exercises of weight training (Based on 1 repetition maximum test - 1RM) for large muscle groups. The aerobic exercise was performed on a treadmill, at a speed of 5.5 km/h and intensity (imposed by treadmill inclination and heart rate) between ventilatory threshold 1 and 2 intensities. After 5 weeks of training, 1RM test was performed again to readjust the resistance load and aerobic intensity was readjusted by heart rate predicted in the incremental test.
Study NCT03053271 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATR-101
Description: During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.
Study NCT03053271 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
Study NCT01926665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Starting dose: 20/20 mg/m2 by vein on Days 1, 2, 15, and 16 of each 28 day cycle.
Study NCT01926665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 4 mg by vein or mouth prior to each Carfilzomib dose in Cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, it should be restarted and administered prior to subsequent doses for reactions.
Study NCT02008045 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Brain MRI without Contrast
Study NCT02008045 — intervention group
Intervention type: BEHAVIORAL
Intervention: Neurodevelopmental Testing
Description: Validated battery of neurodevelopmental and psychological tests.
Study NCT02009007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dopamine
Description: continuous infusion during operation
Study NCT02009007 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine
Description: continuous infusion of phenylephrine during operation
Study NCT01235429 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partners in Care
Description: Diabetes self-management education
Study NCT01738711 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy
Description: Patient receive 2-6 sessions depending on individual need. first session is 1 hour duration with additional sessions approximately 30 minutes.
Study NCT00562965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inotuzumab ozogamicin
Description: IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
Study NCT00562965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
Study NCT00562965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: intravenous rituximab at a dose of 375 mg/m2 on day 1
Study NCT00562965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
Study NCT00562965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Description: intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
Study NCT00562965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone/prednisolone
Description: oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
Study NCT05305027 — intervention group
Intervention type: BEHAVIORAL
Intervention: Prompt diagnois pregnancy outcome
Study NCT00562965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mitoxantrone
Description: mitoxantrone 10 mg/m2 intravenous on day 2
Study NCT02105766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Immunosuppressant
Study NCT02105766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Immunosuppressant
Study NCT00562965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fludarabine
Description: fludarabine 25 mg/m2 intravenous on days 2 through 4
Study NCT00562965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: oral dexamethasone 20 mg/day on days 1-5
Study NCT04442854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive behavioral group therapy
Description: A 8-session cognitive behavior group intervention tailor-made for Mainland Chinese university students in Hong Kong
Study NCT06128317 — intervention group
Intervention type: OTHER
Intervention: no intervention is intended.
Description: no intervention is intended.